Previous 10 | Next 10 |
CANTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, to...
Gainers: Datasea (DTSS) +90%.Lexicon Pharmaceuticals (LXRX) +85%.Pennsylvania Real Estate Investment Trust (PEI) +50%.DPW Holdings (DPW) +36%.Organogenesis (ORGO) +34%.Acacia Communications (ACIA) +33%.Bicycle Therapeutics (BCYC) +31%.AeroVironment (AVAV) +29%.Maxar Technologie...
Gainers: Organogenesis Holdings (ORGO) +33%. Lexicon Pharmaceuticals (LXRX) +30%. NantKwest (NK) +27%. Oragenics (OGEN) +25%. Bicycle Therapeutics (BCYC) +23%.Losers: Viveve Medical (VIVE) -23%. Cassava Sciences (SAVA) -12%. Timber Pharmaceuticals (TMBR) -11%. InflaRx N.V. (IFRX) -9...
Express (EXPR) +62% as company lines up new financing.DPW Holdings (DPW) +57% as pre-orders for residential level 2 EV chargers have begun on Amazon.Pingtan Marine Enterprise (PME) +43% on announcing FY 2021 guidance.ZW Data Action Technologies (CNET) +38%. after the company wa...
Organogenesis (ORGO) has enrolled the first patient in its pivotal Phase 3 trial evaluating ReNu, a cryopreserved amniotic suspension allograft, for the management of symptoms associated with knee osteoarthritis ((OA)).The 474-subject study will evaluate safety and efficacy of ReNu....
CANTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets,...
Organogenesis (ORGO) expects Q4 net revenue of between $104.6M-106M, up 40% to 42% compared tp same quarter prior year.Net revenue from Advanced Wound Care products of between $92M-93.2M, up 45-47% Y/Y.Net revenue from Surgical & Sports Medicine products of between $12.6M-12.8M, up 1...
CANTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, to...
The FDA has granted Organogenesis Holdings's (ORGO) ReNu, a cryopreserved amniotic suspension allograft for the management of symptoms associated with knee osteoarthritis ((OA)), its Regenerative Medicine Advanced Therapy ((RMAT)) designation.RMAT designation program is meant to expedite...
FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated with Knee Osteoarthritis RMAT Designation Enables Closer FDA Interactions to Support Accelerated Approval CANTON, Mass., Jan. 11, ...
News, Short Squeeze, Breakout and More Instantly...
Organogenesis Holdings Inc. Company Name:
ORGO Stock Symbol:
NASDAQ Market:
Organogenesis Holdings Inc. Website:
CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, to...
2024-06-28 10:00:07 ET Brooks O'Neil from Lake Street issued a price target of $5.00 for ORGO on 2024-06-28 08:01:00. The adjusted price target was set to $5.00. At the time of the announcement, ORGO was trading at $2.64. ORGO currently trades -43.21% versus its 52 week ...
CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today an...